Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Bone marrow transplantation in AML, and socioeconomic class: a UK population-based cohort study

Authors: Fatima Bhayat, Emma Das-Gupta, Richard Hubbard

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

We have previously shown that in the UK mortality in people with Acute Myeloid Leukaemia (AML) was nearly 50% greater among the most socio-economically deprived. The aim of this study was to determine whether AML patients from lower socioeconomic classes had a lower chance of receiving a bone marrow transplant.

Methods

Using Hospital Episode Statistics (HES) data, we identified all incident cases of AML admitted to UK hospitals between 1998 and 2007. We calculated the number of bone marrow transplantations undertaken in AML patients, stratifying our results by gender, age at diagnosis, year of diagnosis, degree of socioeconomic deprivation and co-morbidity. We used logistic regression to calculate odds ratios for bone marrow transplantation, adjusting for gender, age at diagnosis, year of diagnosis, degree of socioeconomic deprivation and co-morbidity score.

Results

We identified a total of 23 910 incident cases of AML over this 10-year time period, of whom 1 140 (4.8%) underwent BMT. Bone marrow transplantation declined with increasing socioeconomic deprivation (p for trend < 0.001) such that people in the most deprived socioeconomic quintile were 40% less likely to have a transplant than those in the most advantaged group (Odds Ratio 0.60, 95% confidence interval 0.49, 0.73), even after adjusting for gender, age at diagnosis, year of diagnosis and co-morbidity.

Conclusion

This large cohort study demonstrates that AML patients from lower socioeconomic classes are less likely to undergo bone marrow transplantation than their better off counter-parts.
Literature
1.
go back to reference Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R: The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer. 2009, 9 (1): 252-10.1186/1471-2407-9-252.CrossRefPubMedPubMedCentral Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R: The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer. 2009, 9 (1): 252-10.1186/1471-2407-9-252.CrossRefPubMedPubMedCentral
2.
go back to reference Griggs JJ, Culakova E, Sorbero MES, van Ryn M, Poniewierski MS, Wolff DA, Crawford J, Dale DC, Lyman GH: Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy.[see comment]. Journal of Clinical Oncology. 2007, 25 (3): 277-284. 10.1200/JCO.2006.08.3063.CrossRefPubMed Griggs JJ, Culakova E, Sorbero MES, van Ryn M, Poniewierski MS, Wolff DA, Crawford J, Dale DC, Lyman GH: Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy.[see comment]. Journal of Clinical Oncology. 2007, 25 (3): 277-284. 10.1200/JCO.2006.08.3063.CrossRefPubMed
3.
go back to reference Campbell NC, Elliott AM, Sharp L, Ritchie LD, Cassidy J, Little J: Impact of deprivation and rural residence on treatment of colorectal and lung cancer. British Journal of Cancer. 2002, 87 (6): 585-590. 10.1038/sj.bjc.6600515.CrossRefPubMedPubMedCentral Campbell NC, Elliott AM, Sharp L, Ritchie LD, Cassidy J, Little J: Impact of deprivation and rural residence on treatment of colorectal and lung cancer. British Journal of Cancer. 2002, 87 (6): 585-590. 10.1038/sj.bjc.6600515.CrossRefPubMedPubMedCentral
4.
go back to reference McGory ML, Zingmond DS, Sekeris E, Bastani R, Ko CY: A patient's race/ethnicity does not explain the underuse of appropriate adjuvant therapy in colorectal cancer. Diseases of the Colon & Rectum. 2006, 49 (3): 319-329.CrossRef McGory ML, Zingmond DS, Sekeris E, Bastani R, Ko CY: A patient's race/ethnicity does not explain the underuse of appropriate adjuvant therapy in colorectal cancer. Diseases of the Colon & Rectum. 2006, 49 (3): 319-329.CrossRef
7.
go back to reference Hall W, Ramachandran R, Narayan S, Jani A, Vijayakumar S: An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer. 2004, 4 (1): 94-10.1186/1471-2407-4-94.CrossRefPubMedPubMedCentral Hall W, Ramachandran R, Narayan S, Jani A, Vijayakumar S: An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer. 2004, 4 (1): 94-10.1186/1471-2407-4-94.CrossRefPubMedPubMedCentral
8.
go back to reference Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, et al: The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial. Blood. 1998, 92 (7): 2322-2333.PubMed Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, et al: The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial. Blood. 1998, 92 (7): 2322-2333.PubMed
9.
go back to reference Muss HB: Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status. Journal of the National Cancer Institute Monographs. 2001, 52-55. 30 Muss HB: Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status. Journal of the National Cancer Institute Monographs. 2001, 52-55. 30
10.
go back to reference Munro AJ, Bentley AHM: Deprivation, comorbidity and survival in a cohort of patients with colorectal cancer. Eur J Cancer Care (Engl). 2004, 13 (3): 254-262. 10.1111/j.1365-2354.2004.00480.x.CrossRef Munro AJ, Bentley AHM: Deprivation, comorbidity and survival in a cohort of patients with colorectal cancer. Eur J Cancer Care (Engl). 2004, 13 (3): 254-262. 10.1111/j.1365-2354.2004.00480.x.CrossRef
Metadata
Title
Bone marrow transplantation in AML, and socioeconomic class: a UK population-based cohort study
Authors
Fatima Bhayat
Emma Das-Gupta
Richard Hubbard
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-514

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine